Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EberprotR for dry age-related macular degeneration
ISRCTN12733334Phase 2Terminated
- Sponsor
- Ufa Eye Research Institute
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nepidermin in age-related macular degeneration (AMD) (2 arms), sponsored by Ufa Eye Research Institute. Primary endpoint: Size of geographic atrophy at 6 months. Started Apr 2020; status: terminated.
02
Drugs
nepidermin
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on ISRCTN12733334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12733334.